Karyopharm Therapeutics 株価情報 (NASDAQ: KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) 株価情報

KARYOPHARM THERAPEUTICS INC

Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy. The abstract contains data on selinexor monotherapy in a hard-to-treat, heavily pretreated myelofibrosis patient population from the Phase 2 XPORT-MF-035 trial.

Biotech

News

General

KPTI

Karyopharm Announces Poster Presentation On Selinexor In Myelofibrosis At The 2025 EHA Annual Meeting

WIIM

Karyopharm Therapeutics shares are trading lower after several firms cut their respective price targets on the stock.

Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported mixed financial results for the <a href="https://www.benzinga.com/quote/KPTI/earnings">first quarter on Monday</a>.
The company posted quarterly losses of $2.77 per share which beat the analyst consensus estimate of losses of $4.16 per share. The company reported quarterly sales of $30.02 million which missed the analyst consensus estimate of $35.24 million.
&#8220;We are pleased that our Phase 3 SENTRY trial in patients with JAKi-naïve myelofibrosis has passed its pre-specified futility analysis and continues as planned without modifications. Our conviction in this trial is further strengthened by our new data in hard-to-treat myelofibrosis patients where we observed spleen volume reduction, symptom improvement, hemoglobin stabilization and evidence of disease modification with selinexor monotherapy, addressing all four hallmarks of the disease,&#8221; said Richard Paulson, President and Chief Executive Officer of Karyopharm.
Karyopharm Therapeutics affirmed FY2025 sales guidance of $140.00 million to $155.00 million versus market estimates of $149.32 million.
Karyopharm Therapeutics shares fell 15.6% to trade at $5.17 on Tuesday.
These analysts made changes to their price targets on Karyopharm Therapeutics following earnings announcement.
<ul class="wp-block-list">
<li>Baird analyst Michael Ulz maintained Karyopharm Therapeutics with an Outperform rating and lowered the price target from $54 to $42.</li>
<li>Barclays analyst Peter Lawson maintained the stock with an Overweight rating and raised the price target from $5 to $10.</li>
<li>RBC Capital analyst Brian Abrahams maintained Karyopharm Therapeutics with an Outperform rating and lowered the price target from $34 to $33.</li>
</ul>
Considering buying KPTI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13133540/image-148-1024x611.png" alt="" class="wp-image-913954" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13133540/image-148-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13133540/image-148-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13133540/image-148-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13133540/image-148.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Markets

Analyst Ratings

Trading Ideas

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

RBC Capital analyst Brian Abrahams maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and lowers the price target from $34 to $33.

RBC Capital Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $33

Barclays analyst Peter Lawson maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Overweight and raises the price target from $5 to $10.

Barclays Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $10

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and lowers the price target from $54 to $42.

Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $42

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) affirms FY2025 sales outlook from $140.00 million-$155.00 million to $140.00 million-$155.00 million vs $149.32 million estimate.

Guidance

Karyopharm Therapeutics Affirms FY2025 Sales Guidance of $140.00M-$155.00M vs $149.32M Est

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(2.77) per share which beat the analyst consensus estimate of $(4.16) by 33.41 percent. This is a 42.89 percent increase over losses of $(4.85) per share from the same period last year. The company reported quarterly sales of $30.02 million which missed the analyst consensus estimate of $35.24 million by 14.83 percent. This is a 9.39 percent decrease over sales of $33.13 million the same period last year.

Earnings Beats

Earnings Misses

Karyopharm Therapeutics Q1 EPS $(2.77) Beats $(4.16) Estimate, Sales $30.02M Miss $35.24M Estimate

ACHC

ACHR

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARCT

ARWR

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CHRS

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FGEN

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HBIO

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KSPI

LAND

LEGH

LINC

LSEA

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVIS

MVST

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

<h3>Gainers</h3>
<ul>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares increased by 98.3% to $4.62 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.4 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock moved upwards by 25.91% to $0.29. The market value of their outstanding shares is at $18.3 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 24.78% to $3.85. The company's market cap stands at $2.0 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares rose 22.62% to $8.4. The market value of their outstanding shares is at $53.7 million. </li>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) stock rose 21.28% to $3.77. The company's market cap stands at $228.3 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 17.11% to $2.19. The company's market cap stands at $3.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Serina Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SER#AMEX">SER</a>) stock fell 21.6% to $4.31 during Wednesday's pre-market session. The company's market cap stands at $42.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock declined by 17.37% to $2.38. The market value of their outstanding shares is at $22.4 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares decreased by 16.39% to $5.0. The market value of their outstanding shares is at $112.8 million. </li>
<li>Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) stock fell 15.26% to $5.11. The company's market cap stands at $43.7 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock decreased by 13.62% to $1.65. The market value of their outstanding shares is at $25.0 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares declined by 12.46% to $0.05. The market value of their outstanding shares is at $1.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ENSC

FBRX

GELS

GLYC

INTS

NDRA

NTHI

PTPI

RZLT

SNOA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Shares of Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) rose sharply in today's pre-market trading after reported better-than-expected earnings for its <a href="https://in.benzinga.com/news/earnings/25/04/44674732/levi-strauss-shares-rise-after-mixed-q1-results-details">first quarter on Monday</a>.
Levi Strauss &amp; Co. reported quarterly adjusted earnings of 38 cents per share, which beat the 28 cent analyst consensus estimate.
Levi also said its 2025 guidance remains unchanged, other than to reflect its Dockers business as a discontinued operation, and does not reflect any impact from the recently announced tariffs.
Levi Strauss shares jumped 10.7% to $14.94 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>SaverOne 2014 Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) rose 110.1% to $6.81 in pre-market trading after gaining 22% on Monday.</li>
<li>Galaxy Payroll Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) rose 106.5% to $1.94 in pre-market trading after gaining around 24% on Monday.</li>
<li>P10, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) rose 39% to $13.80 in pre-market trading after gaining 5% on Monday.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) surged 38.4% to $6.77 in pre-market trading.</li>
<li>American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) gained 27.1% to $13.49 in pre-market. American Rebel Holdings, on Monday, issued an update highlighting recent milestones and strategic growth initiatives including successful private placement by H.C Wainwright and media push in South Florida.</li>
<li>MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) rose 24.4% to $23.00 in pre-market trading.</li>
<li>Pursuit Attractions and Hospitality, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRSU#NYSE">PRSU</a>) gained 20.7% to $36.99 in pre-market trading.</li>
<li>Iveda Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) rose 20.6% to $2.81 in pre-market trading.</li>
<li>Unifi, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) gained 18.8% to $5.30 in pre-market trading after falling 5% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) fell 50.5% to $2.00 in pre-market trading after gaining around 5% on Monday.</li>
<li>Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares tumbled 45.7% to $4.07 in pre-market trading after the company announced entry into warrant inducement transaction for approximately $3.7 million in gross proceeds.</li>
<li>CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) fell 29.8% to $8.10 in today's pre-market trading after the company reported preliminary first quarter 2025 financial results.</li>
<li>KNOT Offshore Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNOP#NYSE">KNOP</a>) shares dipped 25.3% to $4.60 in pre-market trading after falling over 4% on Monday.</li>
<li>Shattuck Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) fell 23.8% to $0.9902 in pre-market trading after jumping 77% on Monday.</li>
<li>Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares fell 23.4% to $0.3186 in pre-market trading after surging 90% on Monday.</li>
<li>Graphex Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#NYSE">GRFX</a>) shares fell 19.2% to $0.9210 in pre-market trading following a 7% gain on Monday.</li>
<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) fell 18.8% to $1.08 in pre-market trading after tumbling 30% on Monday.</li>
<li>Collective Mining Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNL#NYSE">CNL</a>) declined 12.2% to $7.31 in pre-market trading.</li>
<li>The Greenbrier Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) dipped 3.9% to $43.00 in pre-market trading as the company posted downbeat results for its second quarter.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44678097/walgreens-rpm-international-and-3-stocks-to-watch-heading-into-tuesday">Walgreens, RPM International And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AREB

BJDX

CHSN

CVRX

GLXG

GRFX

IPDN

IVDA

KNOP

LEVI

PRSU

SOBR

STTK

SVRE

Why Levi Strauss Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and lowers the price target from $75 to $54.

Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $54

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

HC Wainwright &amp; Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and raises the price target from $7 to $56.

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $56

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Karyopharm Therapeutics shares are trading lower after the company announced a 1-for-15 reverse stock split.

Karyopharm Announces 1-for-15 Reverse Stock Split, Effective February 25, 2025

RBC Capital analyst Brian Abrahams reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and maintains $3 price target.

Reiteration

RBC Capital Reiterates Outperform on Karyopharm Therapeutics, Maintains $3 Price Target

HC Wainwright &amp; Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and maintains $7 price target.

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target

Health Care

Karyopharm Says Phase 3 XPORT-EC-042 Trial Of Selinexor As Maintenance Therapy In Advanced or Recurrent TP53 Wild-Type Endometrial Cancer To Focus Enrollment Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkpoint Inhibitors. Increasing Sample Size to 276, Top-Line Data Now Expected in Mid-2026

Stock Split

Press Releases

Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

Comments

Karyopharm Therapeutics

ニュース

パートナーシップ

ベンジンガ・グローバル